目的:观察阿霉素持续静脉输注联合国产长春瑞滨(盖诺 NVB)治疗晚期乳腺癌的疗效及毒副反应,探讨治疗方式改变在化疗中的价值。方法:32例晚期乳腺癌患者,用NA方案:NVB 25 mg/m2 ivgtt d1,8、ADM 50 mg/ m2 civ 96h d1~4。每28天为一周期,至少2周期后评价疗效。观察疗效及毒副反应。结果:32例患者均随访。总共用药170周期,平均5.3周期。CR 5例,PR 18例,RR(CR+PR)71.9% 。初治、复治有效率分别为73.3%、70.6%,二者间无显著性差异(Pgt;0.05)。中位缓解期8.2个月。主要毒副反应为白细胞降低,发生率100%(32/32),32例中Ⅲ～Ⅳ度下降15例(46.9%);恶心、呕吐23例(71.9%),Ⅲ～Ⅳ度4例(12.5%);均发生脱发,Ⅲ～Ⅳ度5例(156%);口腔炎16例(50.0%),Ⅲ～Ⅳ度4例(12.5%);静脉炎2例(6.2%),均为Ⅰ度;心脏毒性发生3例(9.4%),为Ⅰ、Ⅱ度不等。无治疗相关性死亡。结论:阿霉素持续静脉输注与盖诺联合治疗晚期转移性乳腺癌疗效明确,毒副反应可以耐受,远期疗效值得进一步研究。
ObjectiveTo understand the adverse effects of perioperative red blood cells (RBC) transfusion on patients after pancreaticoduodenectomy (PD) so as to provide ideas for reducing postoperative complications and improving prognosis. MethodThe relevant literatures at home and abroad in recent years about studies of perioperative RBC transfusion on postoperative complications (focusing on pancreatic fistula and infection) and prognosis of patients with PD were reviewed. ResultsThe rates of postoperative complications and perioperative RBC transfusion after PD were still higher. The perioperative RBC transfusion might increase the rate of postoperative complications, promote early tumor recurrence, and shorten the disease-free survival and overall survival. At present, with the progress of technology, the perioperative RBC transfusion rate was decreasing. At the same time, with the accelerated development of new blood transfusion technologies such as freeze-drying and refrigeration, the decline rate was still expected to be increased. ConclusionsPerioperative RBC transfusion in PD might have adverse effects on postoperative complications and prognosis. Although further research is still needed to explore its necessary connection, this adverse effect needs to be paid enough attention in clinical practice. Early identification of risk factors, strict transfusion indications and minimizing amount or concentration of RBC transfusion might help to avoid or reduce RBC transfusion and minimize its adverse effects.
目的:研究糖尿病围手术期应用胰岛素泵持续皮下输注胰岛素的临床疗效。方法:68例糖尿病围手术期患者随机分为33例采用胰岛素泵持续皮下输注胰岛素治疗(CSII组),对照组35例采用常规多次皮下注射胰岛素治疗(MSII组),分别对术前、术后的相关指标进行对比研究。结果:治疗后两组各时点血糖均较治疗前显著下降(Plt;0.01)。CSII组达到目标血糖所用的时间明显少于MSII组(2.9比7.2天)(Plt;0.05),血糖达标率优于MSII组(93.%比77.1%)(Plt;0.05),低血糖发生率低于MSII组(9.1%比34.3%)(Plt;0.01)。待手术时间(4.2比9.4天)和住院时间(16比24天)明显缩短(Plt;0.05),但两组住院总费用无差异(Pgt;0.05)。〖结论:CSII在糖尿病患者围手术期中应用疗效及安全性方面优于MSII。
To identify the best evidence in the management of indicator, short and long term of prophylactic platelet transfusion in patient with myelodysplastic syndrome (MDS). We searched the latest evidence-based guidelines in PubMed,reviewed and appraised these guidelines. Clinical decision was made based on the guidelines and the actual patient with MDS. Perfect treatment effect was obtained through evidence-based clinical decision.
目的 观察右美托咪啶复合丙泊酚靶控静脉麻醉在纤维支气管镜检查术中的麻醉效果。 方法 2010年12月－2012年4月，将60例行纤维支气管镜检查术的患者随机分为丙泊酚麻醉组（对照组）和右美托咪啶复合丙泊酚麻醉组（观察组），每组各30例。观察记录不同时点平均动脉压（MAP）、心率、呼吸次数（RR）、脉搏血氧饱和度（SpO2），镇静评分、手术时间、苏醒时间、丙泊酚总用量、不良反应发生率及患者满意度。 结果 所有患者均能顺利完成操作，诱导入睡后观察组MAP、心率下降（P＜0.05），丙泊酚总用量、不良反应发生率均少于对照组（P＜0.05），镇静评分优于对照组（P＜0.05）；两组RR、SpO2、苏醒时间、手术时间及患者满意度差异无统计学意义（P＞0.05）。 结论 右美托咪定复合丙泊酚靶控输注适用于纤维支气管镜检查术麻醉，是一种更加安全有效的麻醉方法。
Objective To investigate the impact of intraoperative red blood cell (RBC) transfusion volume on postoperative oxygenation index in lung transplant recipients. Methods A retrospective analysis was conducted on the clinical data of lung transplant recipients at Wuxi People’s Hospital Affiliated to Nanjing Medical University from 2021 to 2023. Patients were divided into a non-severe primary graft dysfunction (PGD) group and a severe PGD group based on whether their oxygenation index was greater than 200 mm Hg at postoperative 0 h, 24 h, and 48 h. General data and intraoperative RBC transfusion volumes were compared between the two groups to assess their effects on postoperative oxygenation indices at 0 h, 24 h, and 48 h. A binary logistic regression model was constructed to explore the effect values [odds ratios (OR) and their 95% confidence intervals (CI) ] of RBC transfusion volume on oxygenation status at different postoperative time points (0 h, 24 h, 48 h), and the area under the receiver operating characteristic curve (AUC) was calculated to evaluate diagnostic efficacy. Results A total of 351 patients were included, comprising 260 males and 91 females, aged 20 to 77 years. At postoperative 0 h, the OR for intraoperative RBC transfusion was 1.486 (95%CI, P=0.061); at postoperative 24 h, the OR was 3.111 (95%CI, P<0.001); and at postoperative 48 h, the OR was 1.583 (95%CI, P=0.038), indicating that the oxygenation status of lung transplant recipients was significantly affected by the volume of intraoperative transfusion over time. Furthermore, a transfusion volume greater than 975 mL significantly impacted oxygenation at postoperative 24 h and 48 h. Conclusion The volume of intraoperative RBC transfusion has a significant effect on oxygenation status at 24 h and 48 h post-surgery. The amount of RBC transfusion during lung transplantation is associated with the occurrence of severe PGD, and controlling RBC transfusion volume during the procedure may help reduce the incidence of severe PGD.
Objective Historically, perioperative hemoglobin monitoring has relied on calculated saturation, using blood gas devices that measure plasma hematocrit (Hct). Co-oximetry, which measures total hemoglobin (tHb), yields a more comprehensive assessment of hemodilution. The purpose of this study was to examine the association of tHb measurement by co-oximetry and Hct, using conductivity with red blood cell (RBC) transfusion, length of stay (LOS) and inpatient costs in patients having major cardiac surgery. Methods A retrospective study was conducted on patients who underwent coronary artery bypass graft (CABG) and/or valve replacement (VR) procedures from January 2014 to June 2016, using MedAssets discharge data. The patient population was sub-divided by the measurement modality (tHb and Hct), using detailed billing records and Current Procedural Terminology coding. Cost was calculated using hospital-specific cost-to-charge ratios. Multivariable logistic regression was performed to identify significant drivers of RBC transfusion and resource utilization. Results The study population included 18 169 cardiovascular surgery patients. Hct-monitored patients accounted for 66% of the population and were more likely to have dual CABG and VR procedures (10.4% vs. 8.9%, P=0.006 9). After controlling for patient and hospital characteristics, as well as patient comorbidities, Hct-monitored patients had significantly higher RBC transfusion risk (OR=1.26, 95%CI 1.15-1.38,P<0.000 1), longer LOS (IRR=1.08, P<0.000 1) and higher costs (IRR=1.15, P<0.000 1) than tHb-monitored patients. RBC transfusions were a significant driver of LOS (IRR=1.25, P<0.000 1) and cost (IRR=1.22, P<0.000 1). Conclusion tHb monitoring during cardiovascular surgery could offer a significant reduction in RBC transfusion, length of stay and hospital cost compared to Hct monitoring.